With no biology degree and just $3,000, he designed a personalized mRNA vaccine in a world first. Moderna and Merck are ...

The CEO of an Australian IT startup has designed a personalized cancer vaccine for his dog diagnosed with a terminal illness using artificial intelligence (AI) and confirmed its therapeutic effects.

The Exton-based company provides packaging and related services for injectable drugs. Green led West's pandemic response, supplying packaging for vaccine distribution worldwide.

Astellas is pulling out of its $1.6 billion biobucks partnership with CytomX Therapeutics six years after the two companies set out to explore T-cell-engaging bispecifics for the treatment of solid ...

Immunis Inc. has struck a licensing deal with Japanese material manufacturer Toray Industries Inc. to develop a potential treatment for Parkinson’s-associated involuntary movement.

The most valuable employees are those who can connect data, AI systems and people to achieve cross-functional business ...

The pharmaceutical and biotech sectors have seen a flurry of executive movement this month, with leadership changes spanning global giants, clinical-stage biotechs, and specialist pharma companies ...

The move comes as BioNTech shifts to being a multiproduct commercial biotech, allowing Ugur Sahin and Özlem Türeci to transition back into research on next-generation mRNA therapeutics.

It would send a troubling message that politics will determine which medical technologies Idahoans are allowed to use. | ...

Is IBRX a good stock to buy now? We came across a bullish thesis on ImmunityBio, Inc. on r/pennystocks by Bailey-96. In this article, we will summarize the bulls’ thesis on IBRX. ImmunityBio, Inc.’s ...

The leadership changes arrive as BioNTech reported a 57% rise in net losses for 2025.

At Legalweek 2026, the AAA convened legal and technology leaders, including Galia Amram of Open AI, Anna R. Gressel of Freshfields, and Henry Hagen of Moderna, for a discussion on how governance ...